<DOC>
<DOCNO>EP-0621899</DOCNO> 
<TEXT>
<INVENTION-TITLE>
EXPRESSION SIGNAL-PEPTIDE-FREE STAPHYLOKINASES
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3846	C12N964	A61K3800	C12P2108	C07K1640	C12R191	C12N121	C07K1640	C07K120	C12N1558	C12N1502	C12N1509	A61K3843	C12N510	C07K1600	C07K100	C07K1431	C07K1600	C12N121	C12N1509	C07K1441	C12P2108	A61K3800	C12N1502	C12N1557	A61K3900	C12R101	C12N510	A61K3900	C12N964	C07K1441	C07K14195	C07K14195	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C12N	A61K	C12P	C07K	C12R	C12N	C07K	C07K	C12N	C12N	C12N	A61K	C12N	C07K	C07K	C07K	C07K	C12N	C12N	C07K	C12P	A61K	C12N	C12N	A61K	C12R	C12N	A61K	C12N	C07K	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	C12N9	A61K38	C12P21	C07K16	C12R1	C12N1	C07K16	C07K1	C12N15	C12N15	C12N15	A61K38	C12N5	C07K16	C07K1	C07K14	C07K16	C12N1	C12N15	C07K14	C12P21	A61K38	C12N15	C12N15	A61K39	C12R1	C12N5	A61K39	C12N9	C07K14	C07K14	C07K14	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Recombinant staphylokinase polypeptides with plasminogen activator effect, their production and use are disclosed. These polypeptides are produced by expression of DNA sequences free from signal-peptide coding regions.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
MEDAC KLINISCHE SPEZIALPRAEP
</APPLICANT-NAME>
<APPLICANT-NAME>
MEDAC GESELLSCHAFT FUER KLINISCHE SPEZIALPRAEPARATE MBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
ALBRECHT SYBILLE
</INVENTOR-NAME>
<INVENTOR-NAME>
BEHNKE DETLEV
</INVENTOR-NAME>
<INVENTOR-NAME>
GUEHRS KARL-HEINZ
</INVENTOR-NAME>
<INVENTOR-NAME>
HARTMANN MANFRED
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHLOTT BERNHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
BEHNKE, DETLEV
</INVENTOR-NAME>
<INVENTOR-NAME>
GUEHRS, KARL-HEINZ
</INVENTOR-NAME>
<INVENTOR-NAME>
HARTMANN, MANFRED
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHLOTT, BERNHARD
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
DNA sequences coding for staphylokinase polypeptides with 
plasminogen activator effect, 
characterized in that
 the 
sequences are free from regions which code for signal 

peptides. 
DNA sequences according to Claim 1, 
characterized in that
 
they display the nucleotide series according to Figure 1 

(SEQ ID No. 1) plus allelic variants and/or fragments of 
same, if these code for staphylokinase polypeptides with 

plasminogen activator effect. 
DNA sequences according to Claims 1 or 2, 
characterized 
in that
 they display the nucleotide series of the natural 
allelic variants according to Figures 2 (SEQ ID No. 2) or 

3 (SEQ ID No. 3). 
DNA sequence according to Claims 1 or 2, 
characterized in 
that
 it displays the nucleotide series of the fragment 
according to Figure 4 (SEQ ID No. 4). 
DNA sequences according to Claims 1 or 2, 
characterized 
in that
 they display the nucleotide series of the 
artificial allelic variants according to Figures 6 (SEQ 

ID No. 6) or 7 (SEQ ID No. 7). 
Expression plasmids, 
characterized in that
 they contain 
one of the DNA sequences according to Claims 1 to 5, 

operatively linked with expression control sequences, the 
expression plasmids being free from sequences which code 

for staphylokinase signal peptides. 
Expression plasmids according to Claim 6, 
characterized 
in that
 they contain a DNA sequence according to Claims 1 
to 5, operatively linked at their 5'-end with the  

 
translation/initiation region according to Figure 8 (SEQ 

ID No. 8). 
Host cells, 
characterized in that
 they carry expression 
plasmids according to Claims 6 or 7 and are capable of 

the expression of staphylokinase polypeptides with 
plasminogen activator effect. 
Host cells according to Claim 8, c
haracterized in that
 
they are procaryotic cells. 
Host cells according to Claim 9, 
characterized in that
 
they belong to the species 
E
. 
coli.
Host cells according to Claim 9, 
characterized in that
 
they belong to the genus 
Bacillus spec.
Process for the recombinant production of staphylokinase 
polypeptides with plasminogen activator effect as target 

polypeptide, 
characterized in that
 host cells according 
to Claims 8 to 11 are cultivated in a suitable medium and 

the target polypeptides are isolated from the host cells. 
Process according to Claim 12, 
characterized in that
 the 
host cells belong to the species 
E
. 
coli.
Process according to Claims 12 or 13, 
characterized in 
that
, for the isolation of the target polypeptide 

a) the host cells are decomposed and the soluble 
portions of the decomposition are separated from the 

insoluble portions, 
b) the soluble portions are passed directly onto an ion 
exchanger,  

 
c) the target polypeptide is selectively eluted from 
the ion exchanger with an aqueous NaCl solution, 
d) the eluate is conducted directly to a hydrophobic 
interaction chromatography after enrichment with 

NaCl and 
e) the target polypeptide is selectively eluted with a 
falling NaCl gradient from the hydrophobic 

interaction chromatography medium and then obtained 
from the eluate. 
Process according to Claim 14, 
characterized in that
 the 
NaCl concentrations in the stages are 


c) from 0 to 500 mM, 
d) from 2.0 to 30 M and 
e) from 20 to 30 M as initial concentration and from 15 
to 100 mM as final concentration. 
Process according to claims 12 to 15, characterized in 
that the isolated staphylokinase polypeptide is 

subsequently formulated as a pharmaceutical preparation. 
Process according to claim 16, characterized in that the 
formulation is effected by combination with 

pharmaceutically acceptable diluents, adjuvants or 
carrier agents. 
</CLAIMS>
</TEXT>
</DOC>
